Shuhua Yi

Southwest General Health Center — United States

Medicine · Health Sciences

25h-index2.0kcitations556works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(232), Lymphoma Diagnosis and Treatment(208), Multiple Myeloma Research and Treatments(178), Chronic Myeloid Leukemia Treatments(84), Protein Degradation and Inhibitors(42)

Publications555 total

A Scorpion Peptide Exerts Selective Anti-Leukemia Effects Through Disrupting Cell Membranes and Triggering Bax/Bcl-2-Related Apoptosis Pathway
Biomolecules·2025Open Access
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Journal of Clinical Oncology·2025· 2 citedOpen Access
EE61 Assessing the Economic Impact of Biosimilars in Europe: A Cost Analysis of Infliximab, Trastuzumab, and Rituximab
Value in Health·2025
EE109 Budget Impact of Introducing an Omalizumab Biosimilar in 23 European Countries
Value in Health·2025
Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China
EClinicalMedicine·2025Open Access
Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma
Advanced Science·2025Open Access
Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S5 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025Open Access
Investigation of Sheng Mai Yin in the treatment of anthracycline-induced frequent premature ventricular contractions in cancer patients: study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial
Frontiers in Cardiovascular Medicine·2025Open Access
Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Blood·2025
Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center
Blood·2025Open Access
Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia
Blood·2025Open Access
Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after BTK inhibitor era
Blood·2025Open Access
page 1 of 28Next →

Frequent Co-authors

Lugui Qiu(29), Dehui Zou(26), Gang An(21), Yan Xu(21), Zengjun Li(20), Shuhui Deng(17), Weiwei Sui(17), Mu Hao(12), Rui Lv(12), Jianxiang Wang(11), Lugui Qiu(9), Wei Liu(9), Yuting Yan(8), Zhen Yu(8), Xiaoyan Feng(7), Meirong Zang(7), Tao Cheng(7), Kun Ru(7), Junyuan Qi(6), Fei Li(6)